Aim: To describe and discuss the evidence for oncological safety of different procedures in oncological breast surgery, i.e. breast-conserving treatment versus mastectomy. Methods: Literature review and discussion. Results: Oncological safety in breast cancer surgery has many dimensions. Breast-conserving treatment has been established as the standard surgical procedure for primary breast cancer and fits to the preferences of most breast cancer patients concerning oncological safety and aesthetic outcome. Conclusions: Breast-conserving treatment is safe. Nonetheless, the preferences of the individual patients in their consideration of breast conservation versus mastectomy should be integrated into routine treatment decisions.

Keywords:
Breast cancer, Mastectomy, Surgery, Surgical therapy, Breast-conserving therapy
1.
Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marmé F, Jäger D, Kauczor H-U, Stieber A, Lindel K, Debus J, Golatta M, Schütz F, Sohn C, Heil J, Schneeweiss A: Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer 2016;16:734.
2.
Moossdorff M, van Roozendaal LM, Schipper RJ, Strobbe LJ, Voogd AC, Tjan-Heijnen VC, Smidt ML: Inconsistent selection and definition of local and regional endpoints in breast cancer research. Br J Surg 2014;101:1657-1665.
3.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thurlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pelissier S, Bellera C, Dabakuyo-Yonli TS: Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2015;26:873-879.
4.
Curran D, van Dongen JP, Aaronson NK, Kiebert G, Fentiman IS, Mignolet F, Bartelink H: Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG). Eur J Cancer 1998;34:307-314.
5.
Chen CM, Cano SJ, Klassen AF, King T, McCarthy C, Cordeiro PG, Morrow M, Pusic AL: Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. Breast J 2010;16:587-597.
6.
Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y, et al.: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-828.
7.
Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, et al.: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-673.
8.
Veronesi U, Banfi A, Salvadori B, Luini A, Saccozzi R, Zucali R, Marubini E, Del Vecchio M, Boracchi P, Marchini S, et al.: Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer 1990;26:668-670.
9.
Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A, Zucali R: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981;305:6-11.
10.
Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995;333:1444-1455.
11.
Morris AD, Morris RD, Wilson JF, White J, Steinberg S, Okunieff P, Arriagada R, Lê MG, Blichert-Toft M, van Dongen JA: Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am 1997;3:6-12.
12.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-1232.
13.
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-1241.
14.
Fortin A, Larochelle M, Laverdiere J, Lavertu S, Tremblay D: Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999;17:101-109.
15.
Rutgers EJ: Quality control in the locoregional treatment of breast cancer. Eur J Cancer 2001;37:447-453.
16.
van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K, Bartelink H: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143-1150.
17.
Litiere S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012;13:412-419.
18.
Zumsteg ZS, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, Traina T, McCormick B, Powell S, Ho AY: Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol 2013;20:3469-3476.
19.
Mamtani A, Morrow M: Why are there so many mastectomies in the United States? Annu Rev Med 2017;68:229-241.
20.
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
21.
Ellis MJ, Perou CM: The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013;3:27-34.
22.
Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
23.
Weigelt B, Baehner FL, Reis-Filho JS: The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220:263-280.
24.
Hennigs A, Riedel F, Marme F, Sinn P, Lindel K, Gondos A, Smetanay K, Golatta M, Sohn C, Schuetz F, Heil J, Schneeweiss A: Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat 2016;160:491-499.
25.
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-1804.
26.
van la Parra RFD, Kuerer HM: Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res 2016;18:28.
27.
Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ: Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012;133:831-841.
28.
Cao JQ, Olson RA, Tyldesley SK: Comparison of recurrence and survival rates after breast-conserving therapy and mastectomy in young women with breast cancer. Curr Oncol 2013;20:e593-e601.
29.
Maishman T, Cutress RI, Hernandez A, Gerty S, Copson ER, Durcan L, Eccles DM: Local recurrence and breast oncological surgery in young women with breast cancer: the POSH Observational Cohort Study. Ann Surg 2017;266:165-172.
30.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.
31.
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G, Mazzarol G, De Cicco C, Manfredi G, Fernandez JR: Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006;7:983-990.
32.
Kreienberg R, Albert US, Follmann M, Kopp IB, Kuhn T, Wockel A: Interdisciplinary GoR level III guidelines for the diagnosis, therapy and follow-up care of breast cancer: short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd 2013;73:556-583.
33.
D'Angelo-Donovan DD, Dickson-Witmer D, Petrelli NJ: Sentinel lymph node biopsy in breast cancer: a history and current clinical recommendations. Surg Oncol 2012;21:196-200.
34.
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017;318:918-926.
35.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:1303-1310.
36.
Chang JM, Kosiorek HE, Dueck AC, Casey WJ, Rebecca AM, Mahabir R, Patel SH, Keole SR, Wong WW, Vargas CE, Halyard MY, Gray RJ, Wasif N, Stucky CH, Pockaj BA: Trends in mastectomy and reconstruction for breast cancer; a twelve year experience from a tertiary care center. Am J Surg 2016;212:1201-1210.
37.
McGuire K, Santillan A, Kaur P, Meade T, Parbhoo J, Mathias M, Shamehdi C, Davis M, Ramos D, Cox C: Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 2009;16:2682-2690.
38.
Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, del Turco MR, Ponti A: Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer 2012;48:1947-1956.
39.
Albornoz CR, Matros E, Lee CN, Hudis CA, Pusic AL, Elkin E, Bach PB, Cordeiro PG, Morrow M: Bilateral mastectomy versus breast-conserving surgery for early-stage breast cancer: the role of breast reconstruction. Plast Reconstr Surg 2015;135:1518-1526.
40.
Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH: Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med 2013;159:373-381.
41.
Portschy PR, Abbott AM, Burke EE, Nzara R, Marmor S, Kuntz KM, Tuttle TM: Perceptions of contralateral breast cancer risk: a prospective, longitudinal study. Ann Surg Oncol 2015;22:3846-3852.
42.
Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M: Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 2017;265:581-589.
43.
Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL: Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 2014;312:902-914.
44.
Li X, You R, Wang X, Liu C, Xu Z, Zhou J, Yu B, Xu T, Cai H, Zou Q: Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res 2016;22:3971-3981.
45.
Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005;103:44-51.
46.
Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collee JM, Jansen L, Kets CM, Keymeulen KB, Koppert LB, Meijers-Heijboer HE, Mooij TM, Tollenaar RA, Vasen HF, Hooning MJ, Seynaeve C: Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer 2015;136:668-677.
47.
Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27:5887-5892.
48.
Al-Ghazal SK, Fallowfield L, Blamey RW: Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer 2000;36:1938-1943.
49.
Howes BH, Watson DI, Xu C, Fosh B, Canepa M, Dean NR: Quality of life following total mastectomy with and without reconstruction versus breast-conserving surgery for breast cancer: a case-controlled cohort study. J Plast Reconstr Aesthet Surg 2016;69:1184-1191.
50.
Kim MK, Kim T, Moon HG, Jin US, Kim K, Kim J, Lee JW, Kim J, Lee E, Yoo TK, Noh DY, Minn KW, Han W: Effect of cosmetic outcome on quality of life after breast cancer surgery. Eur J Surg Oncol 2015;41:426-432.
51.
Giuliano AE, Hunt KK, Ballman KV, et al.: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-575.
52.
Katz SJ, Lantz PM, Janz NK, Fagerlin A, Schwartz K, Liu L, Deapen D, Salem B, Lakhani I, Morrow M: Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol 2005;23:5526-5533.
53.
Covelli AM, Baxter NN, Fitch MI, McCready DR, Wright FC: ‘Taking control of cancer': understanding women's choice for mastectomy. Ann Surg Oncol 2015;22:383-391.
54.
Morrow M, Jagsi R, Alderman AK, Griggs JJ, Hawley ST, Hamilton AS, Graff JJ, Katz SJ: Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 2009;302:1551-1556.
55.
Griepsma M, de Roy van Zuidewijn DB, Grond AJ, Siesling S, Groen H, de Bock GH: Residual breast tissue after mastectomy: how often and where is it located? Ann Surg Oncol 2014;21:1260-1266.
56.
Arriagada R, Lê MG, Guinebretiere JM, Dunant A, Rochard F, Tursz T: Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol 2003;14:1617-1622.
57.
van der Sangen MJ, van de Wiel FM, Poortmans PM, Tjan-Heijnen VC, Nieuwenhuijzen GA, Roumen RM, Ernst MF, Tutein Nolthenius-Puylaert MC, Voogd AC: Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤ 40 years. Breast Cancer Res Treat 2011;127:207-215.
58.
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Collette L: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259-3265.
59.
Recio-Saucedo A, Gerty S, Foster C, Eccles D, Cutress RI: Information requirements of young women with breast cancer treated with mastectomy or breast conserving surgery: a systematic review. Breast 2016;25: 1-13.
60.
Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, Wong JS, Punglia RS, MacDonald SM, Harris JR: Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat 2017;161:173-179.
61.
Throckmorton AD, Esserman LJ: When informed, all women do not prefer breast conservation. J Clin Oncol 2009;27:484-486.
62.
Houssami N, Macaskill P, Marinovich ML, Dixon JM, Irwig L, Brennan ME, Solin LJ: Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer 2010;46:3219-3232.
63.
Kolben T, Schwarz TM, Goess C, Blume C, Degenhardt T, Engel J, Wuerstlein R, Ditsch N, Harbeck N, Kahlert S: Surgical management of ipsilateral breast tumor recurrence. Int J Surg 2015;23:141-146.
64.
Katz SJ, Morrow M: The challenge of individualizing treatments for patients with breast cancer. JAMA 2012;307:1379-1380.
65.
Bieber C, Nicolai J, Gschwendtner K, Muller N, Reuter K, Buchholz A, Kallinowski B, Harter M, Eich W: How does a shared decision-making (SDM) intervention for oncologists affect participation style and preference matching in patients with breast and colon cancer? J Cancer Educ 2016, in press. DOI: 10.1007/s13187-016-1146-7
66.
Lostumbo L, Carbine NE, Wallace J: Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010;(11):CD002748.
67.
Schmidt H, Cohen A, Mandeli J, Weltz C, Port ER: Decision-making in breast cancer surgery: where do patients go for information? Am Surg 2016;82:397-402.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.